Press Enter to search · Esc to close
Metabolic dysfunction-associated fatty liver disease has slipped into the mainstream of metabolic health. Here's what the newest evidence says about screening, food, and the people most at risk.
A 40,000-person Chinese cohort found that a number you can calculate from a routine lipid panel tracks with incident aortic valve calcification — and inflammation explains part of the link.
A new flow-NMR study cracks open how a marketed GLP-1 drug quietly rearranges itself in solution — and why that matters for the next generation of injectables busy men will actually use.
A 26-week Phase 2 trial pits a once-daily oral non-peptide against dulaglutide — and the β-cell and insulin-sensitivity signals are hard to ignore.
New research links sore thumbs and stuck fingers to metabolic dysfunction, hints that a bone drug may help blood sugar, and maps the inflammation behind gestational diabetes. The thread connecting them: metabolic health is a whole-body story.
A 24-week randomized trial is directly testing whether trading sugary drinks for low-fat cow's milk or fortified soymilk shrinks the fat hiding in your liver. Here's what tired parents should know now.
A dual GIP/GLP-1 agonist already changing diabetes and obesity care is now posting credible early signals against the fatty-liver disease that often travels with them.
A new Raine Study analysis of 638 twenty-two-year-olds finds that beans, lentils, broccoli and their cousins track with lower cardiometabolic risk — sharpening the 'eat your vegetables' message for a generation already worried about long-term heart and metabolic health.
Three new human studies — a decade-long cohort, a systematic review, and a biomarker case-control trial — sketch an emerging toolkit for spotting dysglycemia before it hardens into disease.
A 2026 meta-analysis pools a decade of evidence on how common metabolic syndrome has become — and how much of it tracks back to the lifestyle levers we actually control.